艾昆纬-处方集控制对五个慢性病治疗领域商业保险患者的影响（英）-2025
The Impact of Formulary Controls on Commercially Insured Patients in Five Chronic Therapeutic Areas
报告摘要
The Impact of Formulary Controls on Commercially Insured Patients in Five Chronic Therapeutic Areas
报告信息
- 文件全名
- 《艾昆纬-处方集控制对五个慢性病治疗领域商业保险患者的影响（英）-2025-12页.pdf》
- 适合读者
- 核心数据
- • Over 75% of commercially insured patients were initially denied coverage when attempting to fill a new
- prescription across the five therapeutic areas analyzed. More than 90% of patients were initially denied in four
- delays exceeding three to five weeks, depending on therapeutic area. Between 17% and 31% of patients
- • Between 64% and 82% of patients who did not overcome their initial payer rejection within a year failed to
- 核心议题
常见问题
《艾昆纬-处方集控制对五个慢性病治疗领域商业保险患者的影响（英）-2025》主要包含哪些内容?
The Impact of Formulary Controls on Commercially Insured Patients in Five Chronic Therapeutic Areas核心数据:• Over 75% of commercially insured patients were initially denied coverage when attempting to fill a new;prescription across the five therapeutic areas analyzed. More than 90% of patients were initially denied in four;delays exceeding three to five weeks, depending on therapeutic area. Between 17% and 31% of patients。
这份报告由哪家机构发布?
本报告由艾昆纬发布,发布于 2025 年。
这份报告覆盖哪一年、篇幅多大?
覆盖 2025 年,全文约 12。
这份报告是免费的吗?如何获取?
本报告免费查阅,登录资料宝后即可在线获取完整内容。
这份报告适合哪些读者?
适合投资人、行业研究员等读者参考。
报告涉及哪些关键议题?
重点分析了保险等议题。
继续阅读
查看全部 →